|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||||||||
| Investment in ZEC, at fair value (cost $345,442 and $47,911 as of September 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||
| Receivable for investments sold | ||||||||||||||||||
| Total assets | ||||||||||||||||||
| Liabilities: | ||||||||||||||||||
| Sponsor's Fee payable, related party | ||||||||||||||||||
| Payable for capital shares redeemed | ||||||||||||||||||
| Total liabilities | ||||||||||||||||||
| Net assets | ||||||||||||||||||
| Paid-in-capital | ||||||||||||||||||
| Accumulated net investment loss | ||||||||||||||||||
| Accumulated net realized loss on investment in ZEC | ||||||||||||||||||
| Accumulated net change in unrealized depreciation on investment in ZEC | ||||||||||||||||||
| Shares issued, no par value (unlimited Shares authorized) | ||||||||||||||||||
| Shares outstanding, no par value (unlimited Shares authorized) | ||||||||||||||||||
| Principal Market NAV per Share | ||||||||||||||||||
Loading...